Thank you for your interest in Molecular Medicine. The journal has recently switched publishers to BMC, who will host all back content. If you notice any missing content, please reach out to us.
Evobrutinib mitigates neuroinflammation after ischemic stroke by targeting M1 microglial polarization via the TLR4/Myd88/NF-κB pathway
Evobrutinib, a third-generation Bruton's tyrosine kinase (BTK) inhibitor, shows great promise for treating neuroinflammatory diseases due to its small molecular size, ease of absorption, and ability to cross t...
